Colistin regained global interest as a consequence of the rising prevalence of multidrug-
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …

The emergence of carbapenem-resistant Gram-negative pathogens poses a serious threat
to public health worldwide. In particular, the increasing prevalence of carbapenem-resistant …

Abstract Objective Both EUCAST and CLSI recommend broth microdilution (BMD) for
antimicrobial susceptibility testing of colistin, but BMD is rarely used in routine microbiology …

Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor
combination that often retains activity against resistant Pseudomonas aeruginosa. The …

Colistin and polymyxin B remain part of the last line of antibiotics for multidrug-resistant
Gram-negative bacteria, such as carbapenem-resistant Enterobacteriaceae. Current joint …

ABSTRACT Ceftazidime-avibactam (CAZ-AVI) is a recently approved β-lactam–β-lactamase
inhibitor combination with the potential to treat serious infections caused by carbapenem …

Introduction The increasing prevalence of infections with multidrug-resistant (MDR),
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …

We describe results from a multicenter study evaluating the Accelerate Pheno system, a first
of its kind diagnostic system that rapidly identifies common bloodstream pathogens from …

In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …

Polymyxins, including polymyxin B and polymyxin E (colistin), are now increasingly being
used worldwide to treat patients with multidrug-resistant (MDR) Gram-negative bacterial …